Skip to main
  1. Stocks
  2. Harmony Biosciences Holdings
  3. Forecast
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is supported by a durable WAKIX franchise, with 3Q26 net revenue expected around $275M and 2026 guidance reaffirmed at $1.00B–$1.04B, signaling continued commercial strength in narcolepsy. The company’s positive outlook is also driven by a visible pipeline across rare neurological diseases, including BP-205, EPX-100, Zygel, and pitolisant programs, which can diversify growth beyond one product. Leadership continuity through the planned 2027 CEO transition, plus a strong June cash balance of $962.5M, supports execution, while the upcoming 4Q26 BP-205 data readout and ongoing exclusivity efforts provide additional catalysts.

Bears say

Harmony Biosciences Hldgs is facing a fundamentally fragile growth profile because WAKIX remains the core revenue driver while the sodium oxybate market can become more competitive, new patient adds may slow more than expected, and earlier-than-expected generic pitolisant competition could pressure the franchise. The pipeline does not sufficiently offset that concentration risk, as several programs across PWS, DM1, DS/LGS, Fragile X syndrome, and EPX-100 still depend on clinical success and commercialization execution, creating meaningful binary downside. Even under a 12% discount rate and 6.0x terminal multiple, the valuation framework is highly sensitive to these uncertainties, with litigation, reimbursement, pricing, and competitor risks further threatening the approximately $3.2 billion firm value assumption.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

HRMY Analyst Forecast & Price Prediction

Get the latest HRMY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HRMY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


HRMY Analyst Forecast & Price Prediction

Get the latest HRMY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HRMY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HRMY stock data and trends